Shares of Maravai LifeSciences Holdings, Inc. (MRVI) surged 5.54% in after-hours trading on Thursday, following news of the company's CEO acquiring common shares. This significant move comes as a vote of confidence from the top executive, potentially signaling positive prospects for the life sciences company.

According to a recent filing, Bernd Brust, Chief Executive Officer of Maravai LifeSciences, reported the acquisition of common shares of the company. While the exact number of shares and the purchase price were not immediately disclosed, insider buying often indicates that company leadership believes the stock is undervalued or that there are positive developments on the horizon.

Maravai LifeSciences, a leading provider of critical products to enable the development of drug therapies, diagnostics, and novel vaccines, has seen increased investor interest following this development. The CEO's decision to increase his stake in the company may be interpreted as a strong signal of the firm's growth potential and could attract further attention from market participants in the coming trading sessions.